Jun 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Immunocore reveals new Phase 1 results for brenetafusp (IMC-F106C), a bispecific ImmTAC targeting PRAME, in melanoma patients previously treated with immune checkpoint inhibitors at ASCO 2024.
This TROPiCS-04 trial compared the effects of Trodelvy (sacituzumab govitecan-hziy; SG) against single-agent chemotherapy in individuals with metastatic urothelial carcinoma (mUC).
Ivonescimab plus chemotherapy approved by NMPA for 2L+ EGFRm NSCLC in China: HARMONi-A Trial shows positive overall survival trend for the combination.